Article
Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Antiviral therapy - 1 Jan 2016
Kinugasa Hideaki, Ikeda Fusao, Takaguchi Kouichi, Mori Chizuru, Matsubara Takehiro, Shiraha Hidenori, Takaki Akinobu, Iwasaki Yoshiaki, Toyooka Shinichi, Yamamoto Kazuhide
Abstract excerpt
BACKGROUND: The efficacy of a direct-acting antiviral agent (DAA) is compromised by the development of drug resistance. The associations between resistance-associated virus (RAV) and therapeutic outcomes have not been well-understood. METHODS: A total of 30 patients with HCV genotype-1b were enrolled and treated for 24 weeks with asunaprevir (ASV) and daclatasvir (DCV). Viral sequences in non-structural (NS)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.